NEUROTROPE, INC.(Symbol: NTRP)

Improving the lives of patients with Cognitive and Neurodevelopmental disorders

2

Certain statements in this presentation, particularly those pertaining to our strategy, constitute forward-

looking statements. Such statements are based upon the current beliefs and expectations of management

and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the

forward-looking statements.

Any statements that are not statements of historical fact (including statements containing the words

“believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered

to be forward-looking statements. There are a number of important factors that could cause actual results or

events to differ materially from those indicated by such forward-looking statements. These factors are

contained in Neurotrope Inc.’s filings with the SEC, including Neurotrope’s Form 10-K for December 31, 2014

and Form S-1 filed on December 1, 2014. We encourage all viewers of this presentation to review the

aforementioned filings.

THESE MATERIALS DO NOT CONSTITUTE AN OFFER TO SELL, OR THE SOLICITATION OF ANY OFFER TO BUY, ANY SECURITIES OF THE COMPANY OR ANY ENTITY WHATSOEVER. ANY SUCH OFFER MAY ONLY BE MADE BY A PRIVATE PLACEMENT MEMORANDUM OR PROSPECTUS ISSUED BY THE COMPANY. ANY REPRESENTATION TO THE CONTRARY BY ANY PARTY SHOULD BE IGNORED.

The full text of Neurotrope’s SEC filings can be found at the SEC’s website

(http://www.sec.gov)

Safe Harbor Statement

3

Overview

Bryostatin lead compound Novel mechanism for treatment of cognitive and

neurodevelopmental disorders Protein Kinase C (PKC) activator enhancing memory and

learning Extensive safety data from approx. 1,500 patients from

NCI trials Active programs in Alzheimer’s disease, Fragile X

Syndrome (FXS) and Niemann-Pick Type C disease (NPC) Successfully completed phase 2a Alzheimer’s disease

safety trial Proof of Concept phase 2b trial for Alzheimer’s disease

approved by FDA 150 patients study in moderately severe to severe

Alzheimer’s disease Granted Orphan Drug Designation by FDA for FXS Ongoing preclinical development for NPC.

4

History

Neurotrope funded in 2013 ($23 million raised) to license the patent portfolio, from the Blanchette Rockefeller Neuroscience Institute (BRNI), for clinical development of Bryostatin

By date of NTRP funding, over $200 million invested in research & development by the National Cancer Institute (NCI) and BRNI

Technology involves activation and up regulation of PKC Extensive publications in peer reviewed journals Bryostatin used for Alzheimer’s disease treatment in FDA-

approved Compassionate Use cases Phase 2a Alzheimer’s disease clinical trial completed in Q4 2014 Letter of intent signed with Worldwide Clinical Trials to

commence Phase 2b proof of concept trial Q2 2015 Received FDA Orphan Drug Designation for Fragile X syndrome

Q1 2015.

5

Bryostatin – Lead Compound

Bryostatin is derived from a marine organism, Bugula Neritina

Bryostatin potent activator of PKC Promotes synaptic function and synaptogenesis Inhibits neuronal cell death

NCI has significant bryostatin supply and through BRNI has supplied NTRP NTRP has sufficient amounts for upcoming Phase 2b

trial In conjunction with Stanford Univ. and Dr. Paul

Wender, bryostatin is being synthesized for commercial use.

6

Scientific Rationale

PKC is known to play a pivotal role in learning and memory Bryostatin is a small molecule, penetrates blood-brain

barrier and activates PKC which: Increases brain-derived neurotropic factor (BDNF) Improves synaptic function Promotes new synapse formation Matures immature synapses Activates enzymes which alters amyloid metabolism and

activates three degradation pathways Activates Anti-apoptotic pathways

In NPC activation of PKC results in phosphorylation of a transport protein resulting in transport of lipids within and out of affected cells.

7

Alzheimer’s disease

Preclinical work at BRNI demonstrated improved memory and learning in two different AD mouse models

Clinical Work FDA approved several Compassionate Use protocols in severe

AD patients Three patients treated, current patient treated for

approximately one year Significant improvement in cognition and activities of daily

living over treatment period Phase 2a clinical trial completed

Bryostatin appeared safe and well tolerated Demonstrated activation of PKC target

Phase 2b proof of concept trial – activities initiated.

PKC and Alzheimer’s Disease

Mouse model demonstrating reduction of PKC in AD brain and increase of PKC following bryostatin

treatment.

8

9

Scientific Rationale (cont.)

Brain Derived Neurotropic Factor

Treatment with bryostatin increases BDNF expression in AD transgenic

mice.

10

Improving Synaptic Function

Treatment with bryostatin increases total dendritic spine count in AD transgenic mice

– Improving synaptic function.

11

Synapse Formation

Treatment with bryostatin increases total synapses

in AD transgenic mice.

12

PKC Activation and Learning13

Treatment with bryostatin improves memory and learning in Tg2576 AD

transgenic mice.

14

PKC Activation and Learning

0

20

40

60

80

100

Esc

ape

late

ncy

(s)

C+Vehicle Tg+BryTG+Vehicle

1st TrialDay 1 2 3 4 5 6

C+Bry

Treatment with bryostatin improves memory and learning in 5X FAD transgenic

mice.

0

1

2

3

Ta

rge

t Q

ua

dra

nt

Ra

tio

NS

C+Ve-

hicle

Tg+Ve-

hicle

Tg+Bry(15)

C+Bry

*

*

Learning Memory

15

Phase 2b Clinical Trial Design 150 moderately severe to severe AD patients

First patient enrolled planned for summer of 2015 Primary efficacy endpoint based on Severe Impairment Battery

Scale (SIB) Secondary efficacy endpoints – Activities of Daily Living (ADL),

Neuropsychiatric Inventory (NPI) and MMSE Three dosing levels of bryostatin vs. placebo Initial dose three months then crossover for three months First three month data targeted 2H 2016 Six month data targeted 1H 2017 World Wide Clinical Trials chosen as CRO

30 sites planned in U.S.

16

Orphan Drug Program – Fragile X Most common single gene cause of

intellectual disability Part of autism spectrum

~135,000 patients in U.S. Preclinical cognitive studies performed at

BRNI Orphan Drug Designation granted Q1

2015 Clinical trial planned to begin Q4 2015.

Fragile X Mouse Model

Treatment with bryostatin for 13 weeks beginning at two months

Biochemical and morphologic effects at the synaptic level that improves synaptic function, matures synapses and increases synapse formation - all resulting in improved cognition.

17

Fragile X Mouse Model

Treatment with bryostatin in FX mouse results in restoration of synapses and

improved memory & learning.

18

19

Orphan Drug Program -Niemann Pick Type C disease

NPC is a lysosomal storage disease affecting mostly children Often causes death within the first two decades of life Originates from a gene defect that results in the inability to

transport lipids within and between cells NTRP signed exclusive licensing agreement with Mt. Sinai

School of Medicine (NY) for the work of Dr. Yiannis Ioannou, an expert in NPC, for use of bryostatin in NPC Dr. Ioannou has shown bryostatin can correct the lipid transport

defect in NPC cell lines NTRP and Mt. Sinai currently investigating bryostatin in NPC

mouse model NTRP goal is to initiate human trials before the end of

2016 based on successful animal experiments.

20

Timeline

Q1 2015 Phase 2a clinical trial AD safety study - COMPLETE Orphan drug designation for Fragile X – GRANTED Enroll additional Compassionate Use patients -

ONGOING

Q2 2015 Initiation of Phase 2b Proof of Concept study for

moderately severe to severe Alzheimer’s patients, FDA approves study

LOI with Worldwide Clinical Trials – SIGNED Tripartite agreement for Fragile X with NTRP, FRAXA

and U of Santiago –SIGNED

21

Timeline

Q3 2015 First patient enrolled in Phase 2b clinical trial

Develop clinical strategy for Fragile X with regulatory agency

Q4 2015 Fragile X Phase 2 PK and safety study initiated.

22

Scientific Collaborations

Alzheimer’s Disease and Bryostatin Blanchette Rockefeller Neuroscience

Institute Stanford University

Synthetic development of bryostatin Bryolog development

Marinus Scientific Harvesting and extraction of natural bryostatin

Clinical Advisory Board (slides follows)

23

Scientific Collaborations (cont.) Fragile X Syndrome

Blanchette Rockefeller Neuroscience Institute Preclinical cognitive studies

FRAXA Research Foundation University of Chile in Santiago/preclinical

behavioral studies Clinical Advisory Board

Rush University Medical Center-Chicago, Seattle Children’s Hospital Cincinnati Children’s Hospital Medical Center

24

Scientific Collaborations (cont.) Niemann-Pick Type C

Icahn School of Medicine at Mount Sinai (NYC) Preclinical in-vitro and in-vivo studies

Albert Einstein School of Medicine (NYC) Preclinical in-vivo studies, CNS pathology

25

Clinical Advisory Board

Dr. Jeffrey L. Cummings, MD, ScD, CCF - Chairman Director of Cleveland Clinic Lou Ruvo Center for Brain Health Professor of Neurology and Psychiatry, Director of MSE Center for AD Research and

Director of the DFJ Center for Neurotherapeutics at UCLA Expert in clinical trial design & analysis, global trial implementation, outcome

measures Authored or edited 30 books and published 600 peer-reviewed papers Past President of Behavioral Neurology Society & American Neuropsych. Association.

Dr. Martin R. Farlow, MD Professor and Vice Chairman of Research, Dept. of Neurology Indiana University Associate Co-Director of the Indiana AD Center and member of gov’t. AD task force Principal Investigator of the Indiana site of the AD Cooperative Study Unit Published 200 peer-reviewed papers.

Dr. Samuel E. Gandy, MD, PhD Mount Sinai Chair in AD Research, Professor of Neurology and Psychiatry at Mount

Sinai Director of the Mount Sinai Center for Cognitive Health and NFL Neurological Care Former Chairman of the National Medical & Scientific Advisory Council of the AD

Association Founding Director of the Farber Institute of Neurosciences, Jefferson Medical College Discovered PKC regulation of amyloid precursor phosphorylation and processing.

26

Clinical Advisory Board (cont.) Dr. Cristina Sampaio, MD, PhD

Chief Medical Officer at CHDI Foundation Professor of Clinical Pharmacology and Therapeutics University of

Lisbon, Portugal Former member of the Committee of Proprietary Medicinal Products

and the Scientific Advice Working Party at the European Medicines Agency.

Dr. Michael Weiner, MD Professor UCSF School of Medicine in Radiology and Biomedical

Imaging Principle Investigator of the AD Neuroimaging Initiative Educated at Mount Sinai and Yale, previously Assistant Professor of

Medicine at Stanford Established the MR Unit at the San Francisco VA Medical Center.

27

Leadership Team

Charles S. Ramat – President, Chief Executive Officer and Board member Extensive operational and general business experience

in both public and private companies Industry focus - Biotechnology, medical devices,

commercial finance, real estate

Paul Freiman – Chairman of the Board Seasoned pharmaceutical executive Former Chairman and CEO Syntex – Sold to Roche for $5

billion+ Board member NovaBay Pharmaceutical (NYSE: NBY) Chairman Chronix BioMedical.

28

Leadership Team (cont.)

Dr. Dan Alkon – Chief Scientific Officer Graduate of Cornell Medical School 30 year career as Medical Director and Lab Chief in US NIH

specializing in memory disorders 14 years as founding Scientific Director of BRNI

Dr. Warren W. Wasiewski – Chief Medical Officer Board certified in Neurology and Pediatrics Over 30 years of medical and pharmaceutical experience Extensive clinical & regulatory experience in Neurology, Pediatrics

and Orphan disease space at AstraZeneca, InfaCare and Alexion

Robert Weinstein, CPA, MBA – Chief Financial Officer Experienced healthcare industry CFO and consultant Successful healthcare private equity fund manager & investment

banker.

29

Current Capitalization Shares

Common Stock 27.6 MM

Series A Convertible Preferred Stock (Convertible @ $1.00 / share) 18.0 MM

Options & Warrants Outstanding (Weighted Avg. E.P. $1.39 / share) 9.0 MM

Total fully diluted shares 54.6 MM

Trading Information

Ticker symbol NTRP

Current share price (5/19/15) $0.96

Capital raised during 2013 $23 million

Cash as of May14, 2015 $4.5 million

Trading and Capitalization

30

End